摘要
索马鲁肽是首款口服胰高血糖素样肽-1受体激动剂,于2019年9月获美国食品和药物管理局批准上市,用于成人2型糖尿病患者的血糖控制。临床试验显示索马鲁肽不仅可以有效控制血糖,还可以减轻体重。最常见的不良反应为恶心、呕吐、腹痛、腹泻、食欲减退、便秘等消化道反应。
Semaglutide is the first oral formulation of glucagon like peptide-1 receptor agonist, which has been approved by U.S. FDA in September 2019 to improve glycemic control in adults with type 2 diabetes mellitus. Clinical trials have shown that semaglutide is effective in achieving glycemic control and reducing body weight. The common adverse reactions are gastrointestinal events such as nausea, vomiting, abdominal pain, diarrhea, decreased appetite and constipation.
作者
胡锦华
胡滨
HU Jin-hua;HU Bin(Department of Pharmacy,Shanghai Fourth People's Hospital,SHANGHAI 200434,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2021年第4期265-269,共5页
Chinese Journal of New Drugs and Clinical Remedies
基金
上海市临床药学重点建设项目(区属)。
